心不全患者のSGLT-2阻害剤: ランダム化比較試験の総合的なメタ分析
Muthiah Vaduganathan1, Kieran F Docherty2, Brian L Claggett1
1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Lancet (London, England)
|August 30, 2022
まとめ
SGLT2阻害剤は,多くの患者の心不全による心血管疾患による死亡と入院を大幅に減少させます. これらの発見は,エジェクション分数に関係なく,SGLT2阻害剤を心不全の基礎療法として支持しています.
科学分野:
- 心臓病科
- 薬理学について
- 臨床試験
背景:
- SGLT2阻害剤は,エジェクション分子が低下した心不全に推奨されます.
- より高いエジェクション分数を持つ患者の場合の効果は確立されていない.
- DELIVER と EMPEROR-Preserved のような大規模な試験は,この知識のギャップを埋めています.
研究 の 目的:
- 心不全におけるSGLT2阻害剤試験のメタ分析を行う.
- 異なるエジェクション分数の範囲での有効性を評価する.
- 心血管疾患による死亡率と 心不全による入院への影響を評価する.
主な方法:
- DELIVERとEMPEROR-保存された試験の予め指定されたメタ解析
- DAPA-HF,EMPEROR-Reduced,およびSOLOIST-WHFの試験を含んでいる.
- 一致したエンドポイントの定義を用いた固定効果メタ分析.
主要な成果:
- SGLT2阻害剤は,複合性心血管疾患による死亡や心不全による入院を減少させた (HR 0. 77).
- 心血管疾患による死亡 (HR 0. 87) と心不全による入院 (HR 0. 72) が一貫して減少した.
- 効果はエジェクション分子のサブグループと介護環境において一貫していました.
結論:
- SGLT2阻害剤は,幅広い患者集団において,心血管疾患による死亡と心不全による入院を減少させる.
- これらの薬は,心不全の基礎療法です. 射出分数に関係なく.
- SGLT2阻害剤は,すべてのタイプの心不全の基礎治療法として実証されています.
関連する概念動画
01:30Heart Failure V: Medical Management
21
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
21
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
491
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
491
01:22Heart Failure Drugs: Diuretics
464
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
464
01:22Heart Failure Drugs: β-Blockers
421
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
421
01:30Heart Failure IV: Classification and Diagnostic Evaluation
27
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
27
01:26Heart Failure Drugs: Inotropic Agents
696
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
696